73 related articles for article (PubMed ID: 21726903)
1. Induction of circulating monocyte chemoattractant protein-1 in women with gonadotropin-releasing hormone agonist.
Matsui S; Yasui T; Uemura H; Yamamoto S; Matsuzaki T; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M
J Reprod Immunol; 2011 Aug; 90(2):227-34. PubMed ID: 21726903
[TBL] [Abstract][Full Text] [Related]
2. Changes in insulin sensitivity during GnRH agonist treatment in premenopausal women with leiomyoma.
Matsui S; Yasui T; Tani A; Kunimi K; Uemura H; Yamamoto S; Kuwahara A; Matsuzaki T; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M
Clin Chim Acta; 2012 Jun; 413(11-12):960-5. PubMed ID: 22366120
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-7 is associated with monocyte chemoattractant protein-1 and soluble E-selectin levels in peripheral blood of newly post-menopausal women.
Yasui T; Saijo A; Uemura H; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M
J Reprod Immunol; 2009 Jul; 81(1):97-102. PubMed ID: 19501916
[TBL] [Abstract][Full Text] [Related]
4. Use of a gonadotropin-releasing hormone agonist to manage perimenopausal women with symptomatic uterine myomas.
Wang PH; Lee WL; Cheng MH; Yen MS; Chao KC; Chao HT
Taiwan J Obstet Gynecol; 2009 Jun; 48(2):133-7. PubMed ID: 19574174
[TBL] [Abstract][Full Text] [Related]
5. Elevated level of plasma vascular endothelial growth factor after gonadotropin-releasing hormone agonist treatment for leiomyomata.
Takeda T; Osuga K; Miyake A; Wakabayashi A; Morishige K; Kimura T
Gynecol Endocrinol; 2008 Dec; 24(12):724-6. PubMed ID: 19172544
[TBL] [Abstract][Full Text] [Related]
6. Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas.
Palomba S; Orio F; Russo T; Falbo A; Cascella T; Doldo P; Nappi C; Lombardi G; Mastrantonio P; Zullo F
Hum Reprod; 2004 Jun; 19(6):1308-14. PubMed ID: 15117890
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral and transdermal estrogen therapies on circulating cytokines and chemokines in postmenopausal women with hysterectomy.
Yasui T; Saijo A; Uemura H; Matsuzaki T; Tsuchiya N; Yuzurihara M; Kase Y; Irahara M
Eur J Endocrinol; 2009 Aug; 161(2):267-73. PubMed ID: 19451213
[TBL] [Abstract][Full Text] [Related]
8. [Assessment of serum levels of adhesion molecules (sICAM-1, sVCAM-1, sE-selectin) in stable and unstable angina and acute myocardial infarction].
Bossowska A; Kiersnowska-Rogowska B; Bossowski A; Galar B; Sowiński P
Przegl Lek; 2003; 60(7):445-50. PubMed ID: 14750416
[TBL] [Abstract][Full Text] [Related]
9. Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant follicle-stimulating hormone on follicular fluid levels of adhesion molecules during in vitro fertilization.
Fornaro F; Cobellis L; Mele D; Tassou A; Badolati B; Sorrentino S; De Lucia D; Colacurci N
Fertil Steril; 2007 Jan; 87(1):39-47. PubMed ID: 17084393
[TBL] [Abstract][Full Text] [Related]
10. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
[TBL] [Abstract][Full Text] [Related]
11. Variations in L-selectin ligand expression in the luteal-phase endometrium after final oocyte maturation with human chorionic gonadotropin compared with a gonadotropin-releasing hormone agonist.
Lipari CW; Zhao Y; King JA; Alexander CJ; Bankowski BB; Lai TH; Garcia J; Vlahos NP
Fertil Steril; 2008 Sep; 90(3):876-8. PubMed ID: 17765234
[TBL] [Abstract][Full Text] [Related]
12. Semiquantitative assessment of MR imaging in prediction of efficacy of gonadotropin-releasing hormone agonist for volume reduction of uterine leiomyoma: initial experience.
Okuda S; Oshio K; Shinmoto H; Tanimoto A; Asada H; Fujii T; Yoshimura Y; Kuribayashi S
Radiology; 2008 Sep; 248(3):917-24. PubMed ID: 18710984
[TBL] [Abstract][Full Text] [Related]
13. [A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone].
Zeng C; Gu M; Huang H
Zhonghua Fu Chan Ke Za Zhi; 1998 Aug; 33(8):490-2. PubMed ID: 10806751
[TBL] [Abstract][Full Text] [Related]
14. Raloxifene reduces circulating levels of interleukin-7 and monocyte chemoattractant protein-1 in postmenopausal women.
Yasui T; Uemura H; Hyodo S; Yamada M; Yamamoto S; Maegawa M; Tsuchiya N; Noguchi M; Yuzurihara M; Kase Y; Irahara M
Atherosclerosis; 2009 Jun; 204(2):471-5. PubMed ID: 18976766
[TBL] [Abstract][Full Text] [Related]
15. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy.
Khan KN; Kitajima M; Hiraki K; Fujishita A; Sekine I; Ishimaru T; Masuzaki H
Hum Reprod; 2010 Mar; 25(3):642-53. PubMed ID: 20008888
[TBL] [Abstract][Full Text] [Related]
16. Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist.
Ozcelik B; Turkyilmaz C; Ozgun MT; Serin IS; Batukan C; Ozdamar S; Ozturk A
Fertil Steril; 2010 Mar; 93(5):1609-14. PubMed ID: 19339002
[TBL] [Abstract][Full Text] [Related]
17. Comparison of follicular fluid and serum cytokine concentrations in women undergoing assisted reproductive treatment with GnRH agonist long and antagonist protocols.
Ficicioglu C; Kumbak B; Akcin O; Attar R; Yildirim G; Yesildaglar N
Gynecol Endocrinol; 2010 Mar; 26(3):181-6. PubMed ID: 19718559
[TBL] [Abstract][Full Text] [Related]
18. Shrinkage effect of gonadotropin releasing hormone agonist treatment on uterine leiomyomas and t(12;14).
Takahashi K; Kawamura N; Ishiko O; Ogita S
Int J Oncol; 2002 Feb; 20(2):279-83. PubMed ID: 11788889
[TBL] [Abstract][Full Text] [Related]
19. [GnRH analogues in the management of uterine leiomyoma].
Matsuo H; Maruo T
Nihon Rinsho; 2006 Apr; 64 Suppl 4():75-9. PubMed ID: 16689288
[No Abstract] [Full Text] [Related]
20. Peritoneal vascular density assessment using narrow-band imaging and vascular analysis software, and cytokine analysis in women with and without endometriosis.
Kuroda K; Kitade M; Kikuchi I; Kumakiri J; Matsuoka S; Kuroda M; Takeda S
J Minim Invasive Gynecol; 2010; 17(1):21-5. PubMed ID: 19892605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
